172 related articles for article (PubMed ID: 29353393)
1.
Roque C; Vasconcelos CA
J Endocrinol Invest; 2018 Sep; 41(9):1019-1028. PubMed ID: 29353393
[TBL] [Abstract][Full Text] [Related]
2. Graves' disease induced by Na(131)I therapy for toxic multinodular goitre.
van Leussen JJ; Edelbroek MA; Talsma MA; de Heide LJ
Neth J Med; 2000 Nov; 57(5):194-7. PubMed ID: 11185482
[TBL] [Abstract][Full Text] [Related]
3. TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre.
Wallaschofski H; Kuwert T; Lohmann T
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):171-4. PubMed ID: 15127319
[TBL] [Abstract][Full Text] [Related]
4. Graves' disease and thyroid associated ophthalmopathy following radioiodine therapy in euthyroid multinodular goiter.
Munigoti S; Samat A; Keston Jones M
Thyroid; 2008 May; 18(5):585. PubMed ID: 18466082
[No Abstract] [Full Text] [Related]
5. Induction of stimulating thyrotropin receptor antibodies after radioiodine therapy for toxic multinodular goitre and Graves' disease measured with a novel bioassay.
Hovens GC; Heemstra KA; Buiting AM; Stokkel MP; Karperien M; Ballieux BE; Pereira AM; Romijn JA; Smit JW
Nucl Med Commun; 2007 Feb; 28(2):123-7. PubMed ID: 17198353
[TBL] [Abstract][Full Text] [Related]
6. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays.
Pedersen IB; Knudsen N; Perrild H; Ovesen L; Laurberg P
Clin Endocrinol (Oxf); 2001 Sep; 55(3):381-90. PubMed ID: 11589682
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
8. Incidence of radioiodine induced Graves' disease in patients with multinodular toxic goiter.
Meller J; Siefker U; Hamann A; Hüfner M
Exp Clin Endocrinol Diabetes; 2006 May; 114(5):235-9. PubMed ID: 16804797
[TBL] [Abstract][Full Text] [Related]
9. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.
Nygaard B; Faber J; Veje A; Hegedüs L; Hansen JM
Thyroid; 1999 May; 9(5):477-81. PubMed ID: 10365679
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
Bakker SC; Zanin DE; Zweers EJ
Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
[TBL] [Abstract][Full Text] [Related]
11. Use of a dosimetry-based RAI protocol for treatment of benign hyperthyroidism optimises response while minimising exposure to ionising radiation.
Miller C; Al-Jabri A; O'Murchada L; Mustafa M; Cooke J; Phelan N; Healy ML
Clin Endocrinol (Oxf); 2024 Jun; 100(6):585-592. PubMed ID: 38567706
[TBL] [Abstract][Full Text] [Related]
12. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
[TBL] [Abstract][Full Text] [Related]
13. Induction of TSH-receptor antibodies in patients with toxic multinodular goitre by radioiodine treatment.
Wallaschofski H; Müller D; Georgi P; Paschke R
Horm Metab Res; 2002 Jan; 34(1):36-9. PubMed ID: 11833000
[TBL] [Abstract][Full Text] [Related]
14. Empiric radioiodine for hyperthyroidism: Outcomes, prescribing patterns, and its place in the modern era of theranostics.
Boehm E; Kao YH; Lai J; Wraight PR; Sivaratnam DA
Clin Endocrinol (Oxf); 2022 Jul; 97(1):124-129. PubMed ID: 35508893
[TBL] [Abstract][Full Text] [Related]
15. Predictors of euthyreosis in hyperthyroid patients treated with radioiodine
Stachura A; Gryn T; Kałuża B; Budlewski T; Franek E
BMC Endocr Disord; 2020 Jun; 20(1):77. PubMed ID: 32487052
[TBL] [Abstract][Full Text] [Related]
16. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
17. Factors predicting remission in hyperthyroid patients after low-dose I-131 therapy: 20 years retrospective study from a tertiary care hospital.
S SY; Padma S; Sundaram PS
Ann Nucl Med; 2024 Mar; 38(3):231-237. PubMed ID: 38277114
[TBL] [Abstract][Full Text] [Related]
18. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
19. The usefulness of conventional and echo colour Doppler sonography in the differential diagnosis of toxic multinodular goitres.
Boi F; Loy M; Piga M; Serra A; Atzeni F; Mariotti S
Eur J Endocrinol; 2000 Sep; 143(3):339-46. PubMed ID: 11022175
[TBL] [Abstract][Full Text] [Related]
20. Vitamin B12 levels are not affected by radioiodine ablation of the thyroid.
Potham SK; Vaikkakara S; Sachan A; Rao SP; Kalawat TC; Ravi P; Sunil E; Rajitha D; Arun M; Sailaja A
Endocr Regul; 2014 Apr; 48(2):77-85. PubMed ID: 24824803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
